Multiple Myeloma - KOL Insight

Description

In which frontline settings is Janssen's widely-used anti-CD38 mAb Darzalex expanding and what factors could increase the prospects of Sanofi's competitor Sarclisa? CAR-T cell therapies such as Janssen's Carvykti may be achieving unprecedented response rates but are hampered by concerns about durability and access. How might readily available bispecific antibody Tecvayli capitalise? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

31 Aug 2023 KOL Bulletin -- Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer

Executive summary

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs)

Approved drugs
- Darzalex (daratumumab; Janssen)
- Sarclisa (isatuximab; Sanofi)
Pipeline drugs
- Modakafusp alfa (TAK-573; Takeda)

Immunomodulatory drugs (IMiDs)

Pipeline drugs
- Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

Apoptosis stimulants

Pipeline drugs
- Venetoclax (Venclexta/Venclyxto; AbbVie/Genentech)

CAR T-cell therapies

Approved therapies
- Abecma (idecabtagene vicleucel; BMS/2seventy bio)
- Carvykti (ciltacabtagene autoleucel; Janssen/Legend Biotech)
Pipeline therapies
- Novel CAR T-cell therapies (Gilead [Kite]/Arcellx's CART-ddBCMA; BMS' BMS-986393)

Bispecific antibodies

Approved drugs
- Tecvayli (teclistamab; Janssen)
Pipeline drugs
- BMCA-targeting bispecific antibodies (Pfizer's elranatamab; Regeneron's linvoseltamab; AbbVie's ABBV-383)
- Bispecific antibodies with novel targets (Janssen's talquetamab; Roche's cevostamab)

Future treatment trends

Key insights summary

Appendix

KOL details
- KOLs from the USA
- KOLs from Europe

KOL Bulletins

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ